You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
S
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Withdrawn
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Tempe, Arizona
  • +7 more
2021-03-15
Mar 15, 2021
C
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Enrolling by invitation
  • Relapsed/Refractory B-cell Lymphomas
  • +8 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
2021-11-30
Nov 30, 2021
U
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
2022-02-07
Feb 7, 2022
J
Zanubrutinib + Venetoclax in CLL/SLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2022-03-16
Mar 16, 2022
D
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-08-09
Aug 9, 2021
U
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Active, not recruiting
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
2021-10-07
Oct 7, 2021
N
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - 2021
Terminated
Has Results
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-02-15
Feb 15, 2022
M
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-07
Apr 7, 2022
M
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Leukemia (SLL)
  • Boston, Massachusetts
  • +6 more
2022-03-14
Mar 14, 2022
N
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active, not recruiting
Has Results
  • Leukemia
  • +3 more
  • PCI 32765
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2021-12-02
Dec 2, 2021
L
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • (no location specified)
2022-02-15
Feb 15, 2022
A
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Nagoya-shi, Aichi, Japan
  • +19 more
2022-02-18
Feb 18, 2022
K
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Active, not recruiting
Has Results
  • Prolymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Ohio State University Medical Center
2021-02-20
Feb 20, 2021
S
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - 2020
Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • TP-0903
  • TP-0903 and ibrutinib combination therapy
  • Phoenix, Arizona
  • +5 more
2022-04-04
Apr 4, 2022
N
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Active, not recruiting
Has Results
  • Safety and Tolerability
  • +3 more
  • Zoster Vaccine Recombinant, Adjuvanted
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-10
Jan 10, 2022
N
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Active, not recruiting
Has Results
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-06
Apr 6, 2022
E
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
Not yet recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • (no location specified)
2022-01-24
Jan 24, 2022
P
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - 2018
Completed
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • +5 more
  • Cleveland, Ohio
    Case Comprehensive Cancer Center
2020-01-14
Jan 14, 2020
F
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - 2016
Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Fludarabine Phosphate
  • +3 more
  • Seattle, Washington
  • +1 more
2020-02-14
Feb 14, 2020
A
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL - 2020
Completed
Has Results
  • Follicular Lymphoma (FL/Indolent NHL)
  • +4 more
  • Huntsville, Alabama
  • +22 more
2022-04-01
Apr 1, 2022
M
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-08
Feb 8, 2021
U
Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
Recruiting
  • Leukemia, Lymphoblastic, Acute, Lymphoma
  • CD19CAT-41BBZ CAR T-cells
  • London, United Kingdom
    University College London Hospital
2020-11-20
Nov 20, 2020
P
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
2021-04-28
Apr 28, 2021
B
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma
  • Birmingham, Alabama
  • +24 more
2022-02-08
Feb 8, 2022